<DOC>
	<DOCNO>NCT01381692</DOCNO>
	<brief_summary>This randomized phase I/II trial study side effect best dose temsirolimus give together bortezomib , rituximab , dexamethasone see well work compare bortezomib , rituximab , dexamethasone alone treat patient untreated relapse Waldenstrom macroglobulinemia relapse refractory mantle cell follicular lymphoma . Bortezomib temsirolimus may stop growth cancer cell block enzymes need cell growth . Bortezomib may also stop growth cancer cell block blood flow tumor . Monoclonal antibody , rituximab , block cancer growth difference way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , dexamethasone , work different way stop growth cancer cell , either kill cell stop dividing . It yet know whether bortezomib , rituximab , dexamethasone effective temsirolimus treat non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Bortezomib , Rituximab , Dexamethasone With Without Temsirolimus Treating Patients With Untreated Relapsed Waldenstrom Macroglobulinemia Relapsed Refractory Mantle Cell Follicular Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) temsirolimus combination bortezomib , rituximab , dexamethasone patient relapse Waldenstrom 's macroglobulinemia relapsed/refractory mantle cell , follicular , marginal zone small lymphocytic lymphoma . ( Phase I ) II . To evaluate whether addition temsirolimus regimen bortezomib , rituximab , dexamethasone improve progression-free survival patient previously untreated relapsed Waldenstrom 's macroglobulinemia . ( Phase II ) SECONDARY OBJECTIVES : I . To define describe toxicity temsirolimus combination bortezomib , rituximab , dexamethasone . ( Phase I ) II . To evaluate time progression bortezomib , rituximab , dexamethasone +/- temsirolimus patient . ( Phase II ) III . To evaluate major minor response 6 cycle therapy bortezomib , rituximab , dexamethasone +/- temsirolimus . ( Phase II ) IV . To evaluate time response duration response bortezomib , rituximab , dexamethasone +/- temsirolimus . ( Phase II ) V. To evaluate toxicity bortezomib , rituximab , dexamethasone +/- temsirolimus . ( Phase II ) VI . To evaluate time next therapy bortezomib , rituximab , dexamethasone +/- temsirolimus . ( Phase II ) VII . To evaluate overall survival bortezomib , rituximab , dexamethasone +/- temsirolimus . ( Phase II ) VIII . To describe treatment-related fatigue , physical functional well-being treatment . ( Phase II ) IX . To compare change treatment related fatigue , physical functional well-being 6 cycle bortezomib , rituximab , dexamethasone +/- temsirolimus . ( Quality Life ) X . To prospectively assess health-related quality life longitudinally ( pre-treatment 3 year follow-up assessment ) among trial participant . ( Quality Life ) XI . To describe treatment-related peripheral neuropathy associate bortezomib neurotoxicity . ( Quality Life ) OUTLINE : This phase I , dose-escalation study temsirolimus follow randomized phase II study . PHASE I : Patients receive temsirolimus intravenously ( IV ) 30-60 minute day 1 , 8 , 15 , 22 ; rituximab IV 30-60 minute day 1 , 8 , 15 , 22 ( course 1 4 ) ; bortezomib IV subcutaneously ( SC ) dexamethasone orally ( PO ) day 1 , 8 , 15 . Courses repeat every 28 day 6 course absence disease progression unacceptable toxicity . PHASE II : Patients randomize 1 2 treatment arm . ARM I : Patients receive rituximab IV 30-60 minute day 1 , 8 , 15 , 22 ( course 1 4 ) bortezomib IV SC dexamethasone PO day 1 , 8 , 15 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . ARM II : Patients receive temsirolimus IV 30-60 minute day 1 , 8 , 15 , 22 rituximab , bortezomib , dexamethasone arm I . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 3 month 2 year , every 6 month 3 year , yearly 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically proven diagnosis For phase I portion ( Arm A , B , C D ) , patient must one following : Relapsed Waldenstrom 's macroglobulinemia Relapsed/refractory mantle cell lymphoma ; previous treatment least one standard regimen longer responsive regimen Relapsed/refractory follicular lymphoma ; previous treatment least one standard regimen longer responsive regimen Relapsed/refractory marginal zone lymphoma ; previous treatment least one standard regimen longer responsive regimen Relapsed/refractory small lymphocytic lymphoma ; previous treatment least one standard regimen longer responsive regimen For phase II portion ( Arm E F ) , patient must diagnosis symptomatic Waldenstrom 's macroglobulinemia , either untreated relapse , confirm presence following : Bone marrow lymphoplasmacytosis &gt; = 10 % lymphoplasmatic cell ( measure within 28 day prior registration ) OR Aggregates sheet one following : lymphocyte , plasma cell lymphoplasmacytic cell bone marrow biopsy ( measure within 28 day prior registration ) Measurable disease define quantitative immunoglobulin M ( IgM ) monoclonal protein &gt; = 1000 mg/dL obtain within 28 day prior registration Cluster differentiation 20 ( CD20 ) positive bone marrow lymph node immunohistochemistry flow cytometry obtain within 28 day prior registration Lymph node biopsy must do = &lt; 28 day prior registration use eligibility criterion study entry Serum protein electrophoresis ( SPEP ) require perform within 28 day prior registration Additional requirement Waldenstrom 's macroglobulinemia ( WM ) patient ( phase I II ) : In addition measurable disease , patient must symptomatic disease define one following : Laboratory study define eligibility ( hemoglobin [ Hgb ] , platelet count , viscosity ) must obtain within 28 day prior registration ; one test obtain , recent one utilized Hemoglobin = &lt; 11 g/dL Hyperviscosity syndrome measure viscosity level &gt; = 4 centipoise NOTE : patient strongly recommend undergo therapeutic plasmapheresis prior initiation therapy Platelet count &lt; 100,000/mm^3 Symptomatic lymphadenopathy , splenomegaly , hepatomegaly Constitutional symptom include fever , night sweat , unexplained weight loss ( least 10 % body weight &lt; 6 month ) Symptomatic cryoglobulinemia Additional requirement WM patient ( phase I ) : Patients must receive previous treatment least one standard regimen longer responsive regimen There must least 21 day since last regimen patient must recover previous treatmentrelated toxicity = &lt; grade 1 Additional requirement WM patient ( phase II ) : For previously treat patient , 4 prior regimen allow If last regimen rituximab must least 6 month since last rituximab dose , without rituximab must least 3 month since last regimen For phase I patient , must least 21 day since last regimen previous nonhematologic treatment related toxicity must resolve = &lt; grade 1 Patients must receive concurrent steroid &gt; 10 mg prednisone ( equivalent ) per day Prior irradiation allow &gt; = 28 day prior registration elapse since date last treatment Fasting serum cholesterol = &lt; 300 mg/dL OR = &lt; 7.75 mmol/L AND fast triglyceride = &lt; 2.5 x institutional upper limit normal ( ULN ) , within 28 day prior registration NOTE : case one threshold exceed , patient include initiation appropriate lipid lowering medication ; patient enrol meet criterion lipid lower medication ; patient must start lipid lower medication cholesterol triglyceride must say level study entry Patients must prior exposure mammalian target rapamycin ( mTOR ) inhibitor ( sirolimus , temsirolimus , everolimus ) Women must pregnant breastfeeding ; female childbearing potential must blood test urine study within 2 week prior registration rule pregnancy ; female childbearing potential woman , regardless sexual orientation whether undergone tubal ligation , meet follow criterion : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) Women childbearing potential sexually active male must use accepted effective method contraception throughout study 8 week follow discontinuation everolimus Patients must history prior malignancy except adequately treat basal cell squamous cell skin cancer insitu cervical cancer ; patient may also cancer patient curatively treat surgery alone patient disease free &gt; = 5 year Platelets &gt; = 75,000 mm^3 Neutrophils &gt; = 1,000 mm^3 Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) = &lt; 2.5 x institutional ULN Direct bilirubin = &lt; 1.5 mg/dL Serum creatinine = &lt; 2.5 mg/dL Patients must test hepatitis B surface antigen ( HBsAg ) hepatitis B core antibody ( antiHBc ) within 28 day registration eligible find positive Patients must severe and/or uncontrolled medical condition condition could affect participation study , include , restrict : Symptomatic congestive heart failure New York Heart Association class III IV Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction within 3 month start study treatment , serious uncontrolled cardiac arrhythmia clinically significant heart disease Severely impaired lung function define spirometry diffuse capacity lung carbon monoxide ( DLCO ) ( correct Hgb ) &lt; 50 % normal predict value and/or oxygen ( O2 ) saturation &lt; 88 % rest room air Active ( acute chronic ) uncontrolled severe infection Patients must Eastern Cooperative Oncology Group ( ECOG ) American College Radiology Imaging Network ( ACRIN ) performance status = &lt; 2 Patients must grade 2 high neuropathy Patients must concurrent use angiotensinconverting enzyme ( ACE ) inhibitor ( angioedema ) , concurrent use strong cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) inducer inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>